User profiles for Mayank Ajmera

Mayank Ajmera

Lead, HEOR, Astellas Pharmaceuticals
Verified email at astellas.com
Cited by 495

Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica

MR Ajmera, A Boscoe, J Mauskopf, SD Candrilli… - Journal of the …, 2018 - Elsevier
Background Neuromyelitis optica (NMO) is characterized by unpredictable attacks on the
optic nerves and spinal cord, causing accumulations of neurological disability that may lead to …

[HTML][HTML] Prescription drug use and polypharmacy among Medicaid-enrolled adults with autism: A retrospective cross-sectional analysis

…, C StPeter, S Poe, N Dwibedi, M Ajmera - Drugs-real world …, 2016 - Springer
Background A lack of gold standard treatment for autism spectrum disorders (ASD), no clear
ASD management guidelines, and lack of evidence-based pharmacological interventions …

An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States

CF Bell, MR Ajmera, J Meyers - Lupus, 2022 - journals.sagepub.com
Introduction Approximately 33–50% of patients with systemic lupus erythematosus (SLE)
develop organ damage within 5 years of diagnosis. Real-world studies that capture the …

Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review

F Passamonti, FH Heidel, RC Parikh, M Ajmera… - Future …, 2022 - Future Medicine
Aim: To assess real-world ruxolitinib treatment patterns and outcomes in patients diagnosed
with primary or secondary myelofibrosis. Materials & methods: Patient medical records were …

Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective …

…, M Kearney, A Hitchens, SD Candrilli, M Ajmera - Clinical Genitourinary …, 2023 - Elsevier
Introduction Urothelial carcinoma (UC) is a malignancy of the urothelium that encompasses
the renal pelvis, bladder, and urethra. Current treatment guidelines for advanced (ie, locally …

A real‐world study of the effect of timing of insulin initiation on outcomes in older Medicare beneficiaries with type 2 diabetes mellitus

…, S Zhou, W Wei, M Ajmera… - Journal of the …, 2015 - Wiley Online Library
Objectives To compare clinical and economic outcomes of early insulin initiation with those
of delayed initiation in older adults with type 2 diabetes mellitus (T2 DM ). Design …

Perception of cancer recurrence risk: more information is better

KM Kelly, M Ajmera, S Bhattacharjee, R Vohra… - Patient education and …, 2013 - Elsevier
OBJECTIVE: Breast cancer is the most common cancer among women worldwide. Given the
advances in extending survival, the number of recently diagnosed breast cancer patients …

[HTML][HTML] Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor …

A Morga, M Ajmera, E Gao, O Patterson-Lomba… - Menopause, 2024 - journals.lww.com
… Morga, Antonia PhD 1 ; Ajmera, Mayank PhD 2 ; Gao, Emily MPH 3 ; Patterson-Lomba,
Oscar PhD 3 ; Zhao, Angela BS 3 ; Mancuso, Shayna DO, FACOG 2 ; Siddiqui, Emad MD 1 ; …

Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive …

M Ajmera, AD Raval, C Shen… - International journal of …, 2014 - Taylor & Francis
Objective To estimate excess health care expenditures associated with gastroesophageal
reflux disease (GERD) among elderly individuals with chronic obstructive pulmonary disease (…

[HTML][HTML] Treatment intensification in type 2 diabetes: a real-world study of 2-OAD regimens, GLP-1 RAs, or basal insulin

…, D Raccah, E Lew, J Meyers, E Nikonova, M Ajmera… - Diabetes Therapy, 2018 - Springer
Introduction Treatment guidelines recommend a stepwise approach to glycemia management
in patients with type 2 diabetes (T2D), but this may result in uncontrolled glycated …